Clinical trials
Hematologic Disease and Disorders clinical trials
Below are recruiting hematologic disease and disorders clinical trials, each written for real people, not researchers. We’re tracking 139 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07362238RecruitingPhase 2
Daratumumab vs Rituximab for pediatric ITP
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
TianjinAges 6–18 - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06799611RecruitingPhase 2
CM336 for immune thrombocytopenia (ITP)
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07299149RecruitingPhase 2
Testing a new triple-drug combination for untreated follicular lymphoma
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Tianjin, Tianjin MunicipalityAges 18–90 - NCT07297563RecruitingPhase 2
Anti-CD38 antibody vs rituximab for hard-to-treat ITP
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07297576Recruiting
Sulforaphane to speed blood recovery after cord blood transplant
This trial tests if a natural compound called sulforaphane can help your blood cells recover faster after a cord blood transplant for high-risk blood cancers. If you qualify, you would receive this supplement along with your transplant.
TianjingAges 18 years+ - NCT07259070RecruitingPhase 1/Phase 2
CAR T-cells targeting BAFF-R for resistant B-cell lymphoma
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07234019RecruitingPhase 2
Rituximab plus anti-CD38 antibody for ITP
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07212335RecruitingEarly Phase 1
Stem cells for low blood counts after CAR-T
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
TianjinAges 18 years+ - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07169487RecruitingPhase 1
Methylene Blue for Side Effects of Cancer Immunotherapy
This trial tests if methylene blue can help people who develop side effects called CRS or ICANS after treatments like CAR-T cells or bispecific antibodies. It is a first-in-human study to find a safe dose.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07165769RecruitingPhase 2
ZGR combo for newly diagnosed spleen lymphoma with large cells
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people newly diagnosed with splenic B-cell lymphoma that has large cells (prominent nucleoli). The goal is to see if this drug combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT07152041RecruitingPhase 3
Pediatric Ph+ B-ALL treatment trial
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT07115654RecruitingPhase 2
A bispecific antibody trial for POEMS syndrome
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
TianjinAges 18–78 - NCT07063225RecruitingPhase 2
Romiplostim for low platelets after chemotherapy
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT06996132RecruitingPhase 2
Combination treatment for aggressive B-cell lymphoma that has returned
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
TianjinAges 18–65 - NCT06936930Recruiting
Reproductive and Mental Health in Aplastic Anemia
This study looks at how aplastic anemia affects reproductive and mental health in adults. By understanding these connections, doctors can provide better support for your overall well-being.
Tianjin, Tianjin MunicipalityAges 18–40 - NCT06926595RecruitingPhase 2
Stem cell transplant with low-dose chemo for graft-versus-host disease prevention
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
Hershey, PennsylvaniaAges 18 years+ - NCT06880380RecruitingPhase 1
CAR-T cell therapy for functional HIV cure
This trial tests whether CAR-T cells can help control HIV without daily antivirals. It is for people with well-controlled HIV who want to explore a potential functional cure.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06855810RecruitingPhase 2/Phase 3
New treatment study for children with T-cell ALL
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hefei, AnhuiAges 1 month–18 years - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06776510RecruitingPhase 1/Phase 2
NAD for immune thrombocytopenia study
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Hematologic Disease and Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematologic disease and disorders?
- Yes. Clin2 currently lists 139 recruiting hematologic disease and disorders studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic disease and disorders trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic disease and disorders trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.